Mobile website
Clinical Research
DCIK cells in adoptive immunotherapy of acute myeloid leukemia: a clinical research
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Abstract Objective: To investigate the clinical anticancer efficacy of cocultured dendritic cells with cytokineinduced killer cells (DCIK) in treating patients with acute myeloid leukemia (AML). Methods: Totally 10 patients, who were diagnosed as AML and completely remitted after chemical therapy in the First Affiliated Hospital of Suzhou University from Jan. 2006 to Dec. 2007, were included in this study. Peripheral blood mononuclear cells (PBMC) isolated from these patients were treated with standard protocol and were induced to DCIK cells, which were identified by flow cytometry. MTT assay was used to evaluate the cytotoxic effect of DCIK cells against K562 cells. The qualified DCIK cells were administered to the patients and the clinical anticancer efficacy, immunological activity and side effects were evaluated. Results: The cultured DCIK cells inhibited the K562 cells by (58.3±3.3) %. In DCIK cells administered to patients, the proportion of CD3+CD56+ cells was (38.4±9.42)%. Among the 10 patients received DCIK therapy, 7 had continuous complete remission (70%), 2 had recurrence and 1 had tumorbearing survival. The ratios of CD4+, CD8+, and CD56+ cells in patients′ peripheral blood obviously increased after DCIK infusion. No patients had serious adverse event. Conclusion: DCIK can induce specific immunoreaction in the immune system and has satisfactory clinical anticancer efficacy in treatment of AML.
Keywords:
Project Supported:
Supported by the Key Research plan of Shanghai Science and Technology commisson (No. 05DZ19311)
Clc Number:
